INSR and cancer: Concerning drug combination synergy, we identified peposertib-gamma-ionizing-radiation (ionizing radiation) (DNA-PKi-IR) and M4076-berzosertib (ATMi-ATRi) as combination treatments that show cross-cancer type variability in efficacy and synergy.